

# Chung H Kok

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3919151/chung-h-kok-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

953  
citations

14  
h-index

30  
g-index

57  
ext. papers

1,134  
ext. citations

4.9  
avg, IF

3.25  
L-index

#	Paper	IF	Citations
52	Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission. <i>Blood</i> , <b>2021</b> , 138, 2559-2559	2.2	
51	COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. <i>Blood</i> , <b>2021</b> , 138, 634-634	2.2	0
50	Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 655201	5.7	3
49	CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 171-175	4.5	
48	Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. <i>Blood Advances</i> , <b>2021</b> , 5, 5107-5111	7.8	2
47	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 433-441	4.5	22
46	COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLF) CML and COVID-19 (CANDID) Study. <i>Blood</i> , <b>2020</b> , 136, 46-47	2.2	10
45	The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2020</b> , 136, 25-27	2.2	3
44	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. <i>Leukemia</i> , <b>2020</b> , 34, 1052-1061	10.7	23
43	Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , <b>2020</b> , 11, 814	4.5	5
42	A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. <i>Blood</i> , <b>2019</b> , 134, 663-663	2.2	
41	Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. <i>Blood Advances</i> , <b>2019</b> , 3, 1610-1621	7.8	20
40	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1000-1004	8.7	14
39	Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. <i>Molecular Genetics and Genomics</i> , <b>2018</b> , 293, 1217-1229	3.1	
38	Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines. <i>Oncotarget</i> , <b>2018</b> , 9, 34735-34747	3.3	6
37	Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib. <i>Blood</i> , <b>2018</b> , 132, 1728-1728	2.2	1
36	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. <i>Leukemia</i> , <b>2018</b> , 32, 2572-2579	10.7	37

35	Increased peroxisome proliferator-activated receptor $\beta$ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. <i>Haematologica</i> , <b>2017</b> , 102, 843-853	6.6	7
34	miR-155 as a potential target of IL-3 signaling in primary AML cells. <i>Leukemia Research</i> , <b>2017</b> , 57, 57-59	2.7	6
33	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. <i>Haematologica</i> , <b>2017</b> , 102, e490-e493	6.6	36
32	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. <i>Cancer Letters</i> , <b>2017</b> , 408, 92-101	9.9	17
31	A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 711-721	5.1	7
30	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. <i>Cancer Genetics</i> , <b>2017</b> , 216-217, 86-90	2.3	8
29	In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy. <i>Blood</i> , <b>2016</b> , 128, 3957-3957	2.2	1
28	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 106	22.4	23
27	High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment. <i>Blood</i> , <b>2015</b> , 126, 1419-1419	2.2	1
26	A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. <i>Blood</i> , <b>2015</b> , 126, 596-596	2.2	1
25	High Peroxisome Proliferator-Activated Receptor-Gamma (PPAR $\gamma$ ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. <i>Blood</i> , <b>2015</b> , 126, 2770-2770	2.2	
24	Interleukin-3-mediated regulation of $\beta$ -catenin in myeloid transformation and acute myeloid leukemia. <i>Journal of Leukocyte Biology</i> , <b>2014</b> , 96, 83-91	6.5	11
23	Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients. <i>Blood</i> , <b>2014</b> , 124, 4515-4515	2.2	1
22	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. <i>Blood</i> , <b>2014</b> , 124, 647-647	2.2	1
21	Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes. <i>Blood</i> , <b>2014</b> , 124, 698-698	2.2	
20	High Plasma Levels of TGF- $\beta$ and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML. <i>Blood</i> , <b>2014</b> , 124, 1788-1788	2.2	
19	The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 557-9	4.5	9
18	Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 884-8	4.5	13

17	HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. <i>Oncotarget</i> , <b>2013</b> , 4, 1933-47	3.3	40
16	Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPAR $\gamma$ ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. <i>Blood</i> , <b>2013</b> , 122, 1470-1470	2.2	
15	The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. <i>Leukemia Research</i> , <b>2012</b> , 36, 110-6	2.7	23
14	The GM-CSF receptor utilizes $\beta$ -catenin and Tcf4 to specify macrophage lineage differentiation. <i>Differentiation</i> , <b>2012</b> , 83, 47-59	3.5	16
13	Genome-wide gene expression profiling identifies overlap with malignant adrenocortical tumours and novel mechanisms of inefficient steroidogenesis in familial ACTH-independent macronodular adrenal hyperplasia. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, L19-23	5.7	4
12	Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 2168-73	11.5	61
11	p53-Dependent transcriptional responses to interleukin-3 signaling. <i>PLoS ONE</i> , <b>2012</b> , 7, e31428	3.7	6
10	Global DNA Methylation Analysis Identifies Key Pathway Differences Between Poor (Low OCT-1 Activity) and Standard Risk CP-CML Patients At Diagnosis. <i>Blood</i> , <b>2012</b> , 120, 3730-3730	2.2	
9	Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.. <i>Blood</i> , <b>2012</b> , 120, 2396-2396	2.2	
8	Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. <i>Nature Genetics</i> , <b>2011</b> , 43, 1012-7	36.3	424
7	Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. <i>Blood</i> , <b>2011</b> , 118, 1675-1675	2.2	1
6	Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,. <i>Blood</i> , <b>2011</b> , 118, 3501-3501	2.2	
5	Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,. <i>Blood</i> , <b>2011</b> , 118, 3540-3540	2.2	
4	GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2010</b> , 116, LBA-3-LBA-3	2.2	8
3	Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. <i>Blood</i> , <b>2009</b> , 114, 4859-70	2.2	51
2	Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. <i>Journal of Leukocyte Biology</i> , <b>2006</b> , 80, 433-47	6.5	28
1	Highly sensitive droplet digital polymerase chain reaction for BCR :: ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. <i>British Journal of Haematology</i> ,	4.5	